BRD4 expression is abnormally upregulated in breast cancer tissues and cells, and the targeted inhibition of BRD4 by pharmacological inhibitors and the genetic loss of function analysis have been shown to significantly inhibit the malignancy of breast cancer cells and concomitantly decrease the fibronectin protein levels [81]. The gene discussed is FN1; the disease is breast cancer.